



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



X-82

Item No. 38765

CAS Registry No.: 1013920-15-4
Formal Name: N-[(3S)-1-[(dimethylamino)carbonyl]-3-pyrrolidinyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide

Synonyms: CM082, Vorolanib

MF: C₂₃H₂₆FN₅O₃


FW: 439.5

Purity: ≥98%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

X-82 is supplied as a solid. A stock solution may be made by dissolving the X-82 in the solvent of choice, which should be purged with an inert gas. X-82 is soluble in acetonitrile.

Description

X-82 is a multi-kinase inhibitor.¹ It inhibits VEGFR2, PDGFR β , FMS-related tyrosine kinase 3 (FLT3), and c-Kit (IC₅₀s = 1.12, 0.13, 0.63, and 0.14 nM, respectively) and is selective for these kinases over RET and AMP-activated kinase α 1 (AMPK α 1; IC₅₀s = 74.1 and 352.2 nM, respectively). X-82 inhibits VEGF-induced proliferation of human umbilical vein endothelial cells (HUVECs; IC₅₀ = 31 nM).² It decreases VEGF-induced capillary tube formation in HUVECs when used at a concentration of 1 μ M and reduces FBS-induced migration of HUVECs at 0.01 or 0.1 μ M. *In vivo*, X-82 (80 mg/kg per day), alone and in combination with the EGFR inhibitor gefitinib (Item No. 13166), reduces tumor volume and growth in an HCC827 non-small cell lung cancer (NSCLC) mouse xenograft model.

References

1. Liang, C., Yuan, X., Shen, Z., *et al.* Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity. *Mol. Ther. Oncolytics* **24**, 577-584 (2022).
2. Zhang, K., Wang, L., Wei, A., *et al.* CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer *in vitro* and *in vivo*. *Thorac. Cancer* **11**(6), 1566-1577 (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/15/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM